CAMBRIDGE, Mass.--(BUSINESS WIRE)--AVEO Pharmaceuticals, Inc. today announced that interim safety and efficacy results from the Phase 2 clinical trial of its lead product AV-951 – a novel, highly potent and selective triple VEGF receptor inhibitor – will be presented during an oral abstract session at the 2009 Genitourinary (GU) Cancers Symposium. This multidisciplinary symposium, co-sponsored by the American Society of Clinical Oncology, the American Society for Therapeutic Radiology and Oncology, and the Society of Surgical Oncology, is being held February 26-28, 2009 at the Orlando World Center Marriott Resort & Convention Center in Orlando, FL.
